Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 585 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Rare Cancers Forum 2026: ESMO Leads European Efforts to Turn Evidence... March 11, 2026 No Glucose? Pancreatic Cancer May Have a Ready Energy Alternative June 22, 2023 Intermittent Fasting March 12, 2021 Taking Time for the Everyday Things in 2024 December 29, 2023 Load more HOT NEWS A “Living Medicine:” Engineered E. coli Shrink Tumors in Mice Working to Close the Cancer Screening Gap Caused by COVID A new target to slow down ageing and reduce blood cancer... Long-Term Follow-Up Confirms a Sustained Reduction in Deaths from Prostate Cancer...
